Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies

Marjana Rahman Sarker, Susan Faye Franks

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Processes such as aberrant redox signaling and chronic low-grade systemic inflammation have been reported to modulate age-associated pathologies such as cognitive impairment. Curcumin, the primary therapeutic component of the Indian spice, Turmeric (Curcuma longa), has long been known for its strong anti-inflammatory and antioxidant activity attributable to its unique molecular structure. Recently, an interest in this polyphenol as a cognitive therapeutic for the elderly has emerged. The purpose of this paper is to critically review preclinical and clinical studies that have evaluated the efficacy of curcumin in ameliorating and preventing age-associated cognitive decline and address the translational progress of preclinical to clinical efficacy. PubMed, semantic scholar, and Google scholar searches were used for preclinical studies; and clinicaltrials.gov, the Australian and New Zealand clinical trials registry, and PubMed search were used to select relevant completed clinical studies. Results from preclinical studies consistently demonstrate curcumin and its analogues to be efficacious for various aspects of cognitive impairment and processes that contribute to age-associated cognitive impairment. Results of published clinical studies, while mixed, continue to show promise for curcumin’s use as a therapeutic for cognitive decline but overall remain inconclusive at this time. Both in vitro and in vivo studies have found that curcumin can significantly decrease oxidative stress, systemic inflammation, and obstruct pathways that activate transcription factors that augment these processes. Future clinical studies would benefit from including evaluation of peripheral and cerebrospinal fluid biomarkers of dementia and behavioral markers of cognitive decline, as well as targeting the appropriate population.

Original languageEnglish
Pages (from-to)73-95
Number of pages23
JournalGeroScience
Volume40
Issue number2
DOIs
StatePublished - 1 Apr 2018

Fingerprint

Curcumin
Curcuma
PubMed
Inflammation
Spices
Polyphenols
Molecular Structure
New Zealand
Semantics
Oxidation-Reduction
Cerebrospinal Fluid
Dementia
Registries
Cognitive Dysfunction
Clinical Studies
Oxidative Stress
Anti-Inflammatory Agents
Transcription Factors
Therapeutics
Antioxidants

Keywords

  • Aging
  • Cognition
  • Curcumin

Cite this

@article{2af297d6421c4eeeb76dcb8a82e7a784,
title = "Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies",
abstract = "Processes such as aberrant redox signaling and chronic low-grade systemic inflammation have been reported to modulate age-associated pathologies such as cognitive impairment. Curcumin, the primary therapeutic component of the Indian spice, Turmeric (Curcuma longa), has long been known for its strong anti-inflammatory and antioxidant activity attributable to its unique molecular structure. Recently, an interest in this polyphenol as a cognitive therapeutic for the elderly has emerged. The purpose of this paper is to critically review preclinical and clinical studies that have evaluated the efficacy of curcumin in ameliorating and preventing age-associated cognitive decline and address the translational progress of preclinical to clinical efficacy. PubMed, semantic scholar, and Google scholar searches were used for preclinical studies; and clinicaltrials.gov, the Australian and New Zealand clinical trials registry, and PubMed search were used to select relevant completed clinical studies. Results from preclinical studies consistently demonstrate curcumin and its analogues to be efficacious for various aspects of cognitive impairment and processes that contribute to age-associated cognitive impairment. Results of published clinical studies, while mixed, continue to show promise for curcumin’s use as a therapeutic for cognitive decline but overall remain inconclusive at this time. Both in vitro and in vivo studies have found that curcumin can significantly decrease oxidative stress, systemic inflammation, and obstruct pathways that activate transcription factors that augment these processes. Future clinical studies would benefit from including evaluation of peripheral and cerebrospinal fluid biomarkers of dementia and behavioral markers of cognitive decline, as well as targeting the appropriate population.",
keywords = "Aging, Cognition, Curcumin",
author = "Sarker, {Marjana Rahman} and Franks, {Susan Faye}",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s11357-018-0017-z",
language = "English",
volume = "40",
pages = "73--95",
journal = "GeroScience",
issn = "2509-2715",
publisher = "Springer International Publishing AG",
number = "2",

}

Efficacy of curcumin for age-associated cognitive decline : a narrative review of preclinical and clinical studies. / Sarker, Marjana Rahman; Franks, Susan Faye.

In: GeroScience, Vol. 40, No. 2, 01.04.2018, p. 73-95.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Efficacy of curcumin for age-associated cognitive decline

T2 - a narrative review of preclinical and clinical studies

AU - Sarker, Marjana Rahman

AU - Franks, Susan Faye

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Processes such as aberrant redox signaling and chronic low-grade systemic inflammation have been reported to modulate age-associated pathologies such as cognitive impairment. Curcumin, the primary therapeutic component of the Indian spice, Turmeric (Curcuma longa), has long been known for its strong anti-inflammatory and antioxidant activity attributable to its unique molecular structure. Recently, an interest in this polyphenol as a cognitive therapeutic for the elderly has emerged. The purpose of this paper is to critically review preclinical and clinical studies that have evaluated the efficacy of curcumin in ameliorating and preventing age-associated cognitive decline and address the translational progress of preclinical to clinical efficacy. PubMed, semantic scholar, and Google scholar searches were used for preclinical studies; and clinicaltrials.gov, the Australian and New Zealand clinical trials registry, and PubMed search were used to select relevant completed clinical studies. Results from preclinical studies consistently demonstrate curcumin and its analogues to be efficacious for various aspects of cognitive impairment and processes that contribute to age-associated cognitive impairment. Results of published clinical studies, while mixed, continue to show promise for curcumin’s use as a therapeutic for cognitive decline but overall remain inconclusive at this time. Both in vitro and in vivo studies have found that curcumin can significantly decrease oxidative stress, systemic inflammation, and obstruct pathways that activate transcription factors that augment these processes. Future clinical studies would benefit from including evaluation of peripheral and cerebrospinal fluid biomarkers of dementia and behavioral markers of cognitive decline, as well as targeting the appropriate population.

AB - Processes such as aberrant redox signaling and chronic low-grade systemic inflammation have been reported to modulate age-associated pathologies such as cognitive impairment. Curcumin, the primary therapeutic component of the Indian spice, Turmeric (Curcuma longa), has long been known for its strong anti-inflammatory and antioxidant activity attributable to its unique molecular structure. Recently, an interest in this polyphenol as a cognitive therapeutic for the elderly has emerged. The purpose of this paper is to critically review preclinical and clinical studies that have evaluated the efficacy of curcumin in ameliorating and preventing age-associated cognitive decline and address the translational progress of preclinical to clinical efficacy. PubMed, semantic scholar, and Google scholar searches were used for preclinical studies; and clinicaltrials.gov, the Australian and New Zealand clinical trials registry, and PubMed search were used to select relevant completed clinical studies. Results from preclinical studies consistently demonstrate curcumin and its analogues to be efficacious for various aspects of cognitive impairment and processes that contribute to age-associated cognitive impairment. Results of published clinical studies, while mixed, continue to show promise for curcumin’s use as a therapeutic for cognitive decline but overall remain inconclusive at this time. Both in vitro and in vivo studies have found that curcumin can significantly decrease oxidative stress, systemic inflammation, and obstruct pathways that activate transcription factors that augment these processes. Future clinical studies would benefit from including evaluation of peripheral and cerebrospinal fluid biomarkers of dementia and behavioral markers of cognitive decline, as well as targeting the appropriate population.

KW - Aging

KW - Cognition

KW - Curcumin

UR - http://www.scopus.com/inward/record.url?scp=85045736294&partnerID=8YFLogxK

U2 - 10.1007/s11357-018-0017-z

DO - 10.1007/s11357-018-0017-z

M3 - Review article

C2 - 29679204

AN - SCOPUS:85045736294

VL - 40

SP - 73

EP - 95

JO - GeroScience

JF - GeroScience

SN - 2509-2715

IS - 2

ER -